| Successful management of Crohn's disease of the ileoanal pouch with infliximab. | |
| | |
MedLine Citation:
|
PMID: 10419926 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study reports the clinical benefit and safety of the murine chimeric anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab, in the treatment of patients who developed findings compatible with Crohn's disease after undergoing colectomy with ileal-pouch anal anastomosis (IPAA) for an original diagnosis of ulcerative colitis. Medical records of 7 patients with Crohn's disease and an IPAA treated with infliximab were reviewed. Clinical response was classified as complete response, partial response, and no response. Concurrent treatment with immune modifier agents and/or antibiotics was recorded. Seven patients with active inflammatory or fistulizing Crohn's disease and an IPAA performed for diagnosis of ulcerative colitis were treated with infliximab after they had no response to conventional therapies. Patients received 1-4 infliximab infusions at a dose of 5 mg/kg. All patients improved clinically. Six patients had a complete response, and 1 had a partial response. Four of the 5 patients with complex perianal and fistulizing disease had closure of all fistula tracts, and 1 patient improved temporarily. Six of the 7 patients underwent concurrent treatment with immune modifier drugs. One patient had myalgias and malaise after the first infliximab infusion and flu-like symptoms after the second one. No other adverse effects were observed. This case series demonstrates that the murine chimeric anti-TNF-alpha monoclonal antibody, infliximab, can be used successfully to treat patients with Crohn's disease involving an IPAA who are refractory to conventional therapies. |
| | |
Authors:
|
E Ricart; R Panaccione; E V Loftus; W J Tremaine; W J Sandborn |
Related Documents
:
|
20410806 - Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopi... 20684016 - Irritable pouch syndrome is characterized by visceral hypersensitivity. 8563886 - Results of cancer surveillance in ulcerative colitis. 19235886 - Low counts of faecalibacterium prausnitzii in colitis microbiota. 9678836 - Bronchial and cutaneous responses in atopic dermatitis patients after allergen inhalati... 17115266 - Ablation of difficult right-sided accessory pathways aided by mapping of tricuspid annu... |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Gastroenterology Volume: 117 ISSN: 0016-5085 ISO Abbreviation: Gastroenterology Publication Date: 1999 Aug |
Date Detail:
|
Created Date: 1999-08-26 Completed Date: 1999-08-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374630 Medline TA: Gastroenterology Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 429-32 Citation Subset: AIM; IM |
Affiliation:
|
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / adverse effects, therapeutic use* Crohn Disease / therapy* Female Humans Male Middle Aged Proctocolectomy, Restorative* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/infliximab |
| Comments/Corrections | |
Comment In:
|
Gastroenterology. 2003 Aug;125(2):631-3; author reply 633
[PMID:
12891580
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes.
Next Document: Pitfalls in the analysis of electrogastrographic recordings.